Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioblastoma × Memantine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Brain Neoplasms 3 Neoplasm Metastasis 2 Lung Neoplasms 2 Cognitive Dysfunction 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Tobacco Use Disorder 1 Small Cell Lung Carcinoma 1 Recurrence 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Neurotoxicity Syndromes 1 Melanoma 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Renal Cell 1

Interventions

Temozolomide 104 Bevacizumab 64 Radiotherapy 45 Radiation 21 Erlotinib Hydrochloride 12 pembrolizumab 10 Magnetic Resonance Spectroscopy 10 Lomustine 10 Vorinostat 9 Irinotecan 9 Nivolumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Immunoglobulin G 7 Disulfides 7 Sorafenib 6 Radiotherapy, Conformal 6 Radiosurgery 6 Drug Therapy 6 Carmustine 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 Everolimus 5 veledimex 4 selinexor 4 sargramostim 4 cediranib 4 Dasatinib 4 Cilengitide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01260467 2015-12-10

Memantine for Recurrent Glioblastoma

University of Rochester

Phase 2 Terminated

4 enrolled 3 charts

Glioblastoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡